Valuation : Veru Inc.

Market Cap 46.89M 40.34M 37.86M 34.64M 64.65M 4.43B 65.16M 448M 174M 2.27B 176M 172M 7.3B P/E 2026 *
-2.71x
P/E 2027 * -2.79x
Enterprise Value 46.89M 40.34M 37.86M 34.64M 64.65M 4.43B 65.16M 448M 174M 2.27B 176M 172M 7.3B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.55%
1 week-0.36%
Current month-2.50%
1 month+20.80%
3 months+21.33%
6 months+8.33%
Current year+27.57%
1 week 2.59
Extreme 2.59
2.82
1 month 2.27
Extreme 2.27
2.89
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2016
Director of Finance/CFO 67 01/01/2013
Chief Tech/Sci/R&D Officer 64 01/04/2018
Director TitleAgeSince
Chairman 65 01/03/2018
Director/Board Member 68 01/10/2016
Director/Board Member 68 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
13/08/26 Buy

Chief Technology Officer

1,800 0.0112%
04/05/26 Free

Director

160,000 0.9969%
04/05/26 Free

Director

102,000 0.6355%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-0.36%-17.52%-74.95% 46.89M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.31%+0.55%+49.48%+92.12% 65.29B
-0.34%+3.62%-12.35%+376.98% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.59%-7.25%+2.89%-15.31% 26.08B
+1.01%+1.38%+26.48%-17.50% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.74%+7.82%+61.20%+167.53% 14.5B
Average +1.09%-2.57%+41.62%+157.72% 28.04B
Weighted average by Cap. +1.17%-2.12%+42.78%+142.29%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.6M -20.27M -18.54M -34.61M -2.37B -34.88M -240M -93.36M -1.21B -94.26M -92.2M -3.91B -37.1M -31.92M -29.96M -27.41M -51.15M -3.51B -51.56M -354M -138M -1.79B -139M -136M -5.77B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
03/09/26 $2.730 -0.73% 28,783
02/09/26 $2.750 +2.23% 202,594
01/09/26 $2.690 -3.93% 203,192
31/08/26 $2.800 +6.67% 250,048
28/08/26 $2.625 -4.20% 92,788
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.750USD
Average target price
24.50USD
Spread / Average Target
+790.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock